A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases

被引：28

作者：

Calderone, Vito

Fragai, Marco

Luchinat, Claudio

Nativi, Cristina

Richichi, Barbara

Roelens, Stefano

机构：

[1] Magnetic Resonance Center, University of Florence, Sesto Fiorentino 50019

[2] Department of Organic Chemistry, University of Florence, Sesto Fiorentino 50019

[3] Department of Chemistry, University of Siena, Siena

[4] Department of Agricultural Biotechnology, University of Florence, Florence

[5] ProtEra S.r.l.

[6] CNR, Istituto di Chimica del Composti Organometallici, Florence

来源：

CHEMMEDCHEM | 2006年 / 1卷 / 06期

关键词：

Albumin interaction; Glycosyl derivatives; Inhibitors; Lipophilicity; Metalloproteinases;

D O I：

10.1002/cmdc.200600020

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Matrix metalloproteinases (MMPs) are a class of Zn-containing hydrolases that participate in a variety of biological processes, and aberrant activity of MMPs has been implicated in a number of diseases including cancer. A new glycoside-containing inhibitor of MMPs, unprecedented among the inhibitors of this family of enzymes, is reported. This inhibitor is water soluble, and displays nanomolar affinity toward several MMPs.

引用

收藏

页码：598 / +

页数：5

相关论文

共 15 条

[1] Recent advances in matrix metalloproteinase inhibitor research [J].

Beckett, RP ;

Davidson, AH ;

Drummond, AH ;

Huxley, P ;

Whittaker, M .

DRUG DISCOVERY TODAY, 1996, 1 (01) :16-26

[2] Conformational variability of matrix metalloproteinases: Beyond a single 3D structure [J].

Bertini, I ;

Calderone, V ;

Cosenza, M ;

Fragai, M ;

Lee, YM ;

Luchinat, C ;

Mangani, S ;

Terni, B ;

Turano, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5334-5339

[3] Tissue inhibitors of matrix metalloproteinases in cancer [J].

Blavier, L ;

Henriet, P ;

Imren, S ;

DeClerck, YA .

INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :108-119

[4] Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases [J].

Cawson, T .

MOLECULAR MEDICINE TODAY, 1998, 4 (03) :130-137

[5] Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].

Coussens, LM ;

Fingleton, B ;

Matrisian, LM .

SCIENCE, 2002, 295 (5564) :2387-2392

[6] Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases [J].

Fragai, M ;

Nativi, C ;

Richichi, B ;

Venturi, C .

CHEMBIOCHEM, 2005, 6 (08) :1345-1349

[7] N-aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases:: further probing of the S1, S1′, and S2′ pockets [J].

Hanessian, S ;

Moitessier, N ;

Gauchet, C ;

Viau, M .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (19) :3066-3073

[8] Development of matrix metalloproteinase inhibitors in cancer therapy [J].

Hidalgo, M ;

Eckhardt, SG .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) :178-193

[9] Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits [J].

MacPherson, LJ ;

Bayburt, EK ;

Capparelli, MP ;

Carroll, BJ ;

Goldstein, R ;

Justice, MR ;

Zhu, LJ ;

Hu, SI ;

Melton, RA ;

Fryer, L ;

Goldberg, RL ;

Doughty, JR ;

Spirito, S ;

Blancuzzi, V ;

Wilson, D ;

OByrne, EM ;

Ganu, V ;

Parker, DT .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (16) :2525-2532

[10] Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty [J].

Masuda, T ;

Nakayama, Y .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (16) :3497-3501